A new synthetic lethal strategy expands the application of PARP inhibitors/cisplatin
Jinrui Wang,
Daniel D. Billadeau,
Ying Zheng,
Da Jia
Affiliations
Jinrui Wang
Key Laboratory of Birth Defects and Related Diseases of Women and Children, Department of Paediatrics, West China Second University Hospital, State Key Laboratory of Biotherapy Sichuan University Chengdu China
Daniel D. Billadeau
Division of Oncology Research, Schulze Center for Novel Therapeutics Mayo Clinic Rochester Minnesota USA
Ying Zheng
Key Laboratory of Birth Defects and Related Diseases of Women and Children, Department of Gynaecologic Oncology, Ministry of Education, West China Second University Hospital Sichuan University Chengdu China
Da Jia
Key Laboratory of Birth Defects and Related Diseases of Women and Children, Department of Paediatrics, West China Second University Hospital, State Key Laboratory of Biotherapy Sichuan University Chengdu China
